

Multiple Myeloma OncoSummit 2020

February 14th, 2020

Intercontinental COEX Hotel, Seoul, Korea

Time	Topic	Moderator / Speaker
17.00 – 18.00	Registration and Dinner	Takeda
18.00 – 18.20	Opening Remarks	Chairperson Prof. Chang-Ki Min
18.20 – 19.30	Novel Frontline Treatments in Multiple Myeloma (40 mins) <ul style="list-style-type: none">• Speaker will present on recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.• With the introduction of novel agents, speaker will review current and future frontline treatments in multiple myeloma <hr/> Risk-Adapted Maintenance Strategies (30 min) <ul style="list-style-type: none">• Speaker will present the current status of maintenance therapy in multiple myeloma and review the clinical data which can provide recommendations for maintenance therapy in multiple myeloma in the era of risk adapted strategies .<ul style="list-style-type: none">○ Maintenance in SCT eligible and non eligible patients○ Maintenance therapy in special populations	Prof Mohamed Mohty <i>(Hospital Saint-Antoine and University Pierre & Marie Curie, Paris, France)</i>
19.30 – 20.30	Optimizing Treatment Strategies in Relapsed/ Refractory Multiple Myeloma and real-world experience from Western countries <ul style="list-style-type: none">• Speaker will review the available data and evidence for novel agents in the relapsed/refractory setting and discuss their key role in tailored treatment strategies aimed at optimising current clinical practice. He will comprehensively review the updates on the novel drug combinations for the management of relapsed/refractory multiple myeloma.• Speaker will present about recent Real-World Evidence from Western countries (Europe, US)<ul style="list-style-type: none">○ Interpreting clinical trial data in multiple myeloma-translating findings to the real-world setting○ Discrepancies between pivotal studies vs real world experience (duration of treatment, efficacy, patient compliance etc)	Prof. Roman Hajek <i>(University of Ostrava, Czech Republic)</i>
20.30– 21.00	“Real World” Evidence on the Efficacy and Safety of novel drugs in Relapsed/Refractory Multiple Myeloma – China experience <ul style="list-style-type: none">• Speaker will present real world treatment in multiple myeloma from comprehensive China experience	Prof. Liu Peng <i>(Zhongshan Hospital, Fudan University, Shanghai, China)</i>
21.00 – 21.30	Panel discussion with international speakers	All
21.30 – 21.35	Closing Remarks	Chairperson Prof. Chang-Ki Min